AUTHOR INDEX

Adler, S.P., 10
Allen, R.H., 185
Almgren, C., 318
Anand, K.J.S., 273, 275, 283, 309, 318
Ananth, C.V., 196
Andiman, W.A., 112

Baltimore, R.S., 1, 33
Beardsley, D.S., 203, 250
Belfort, M.A., 135
Bhutta, A.T., 303
Bianchi, B., 223
Bizzarro, M.J., 26
Bonanno, C., 348
Bottalico, J.N., 176
Boyle, E., 289
Brancazio, L.R., 167
Brown, H., 167
Buonanno, F.S., 243

Carbajal, R., 309
Chapman, R.L., 39
Coustan, D.R., 363

D'Alton, M.E., 331
Denne, S.C., 56
Dildy III, G.A., 135
Douglas, N.C., 332
Dove, L., 348

Ebcioglu, Z., 339
Eble, B., 309
Ehrenkranz, R.A., 47, 48
Erez, O., 142
Espinoza, J., 142
Estes, C.M., 372

Fitzgerald, M., 298
Fuchs, K.M., 331, 339, 363

Gallagher, P.G., 26, 254
Ghidini, A., 232
Golianu, B., 318
Gotsch, F., 142
Grabowski, E.F., 243
Greer, F.R., 89
Grotegut, C.A., 167
Gurewitsch, E.D., 185

Hall, R.W., 273, 275, 289
Hardman, M.P., 275
Hassan, S.S., 142
Hossain, N., 208, 240

Infante-Rivard, C., 213

James, A.H., 167
Jenson, H.B., 1
Johnson, T.L., 185
Johnston, C.C., 283

Kaminsky, L., 126
Kashyap, S., 74
Kennedy, K.A., 61
Kilpatrick, S.J., 159
Kimberlin, D.W., 19
Kinzler, W.L., 126
Kocoshis, S.A., 104
Kominiarek, M.A., 159
Krane, E., 318
Krishnamoorthy, K , 243
Kusanovic, J.P., 142

Langhoff-Roos, J., 219
Lehr, V.T., 323
Lowery, C.L., 275
Lucke, J.F., 61
Lykke, J.A., 219

Manning, N., 275
Marks, P.W., 227
Mazaki-Tovi, S., 142
Mecacci, F., 223
Meek, J., 298
Mittal, P., 142
Morales, Y., 83
Moyer-Mileur, L.J., 96

Nigro, G., 10

Paidas, M.J., 203, 208, 219, 223, 232
Paintsil, E., 112
Patrizio, P., 204, 232
Pedroza, C., 61
Pereira, L., 10
Pieralli, A., 223
Pineles, B.L., 142
Poindexter, B.B., 47, 56

Ranger, M., 283
Ratner, L.E., 331
Restaino, S., 354
Ricci, S., 232
Romero, R., 142

Sauer, M.V., 332
Schanler, R.J., 83
Schelonka, R.L., 2
Seybold, J., 318
Shah, M., 332
Slater, R., 298
Smulian, J.C., 125, 135
Stack, G., 262
Steiner, L.A., 254

Taddio, A., 323
Than, N.G., 142
Tortoli, P., 232
Triche, E.W., 240
Tyson, J.E., 61

Urban, G., 232

Vergani, P., 232
Vitiello, D., 204

Waites, K.B., 2
Wessel, J.J., 104
Westhoff, C., 372
Wilt, J., 354
Wu, D.W., 339, 354
Wu, Y., 262

Young, B., 219
Young, T., 289

SUBJECT INDEX

Aase syndrome, 259
Abdominal skin reflexes (ASR), 285-286
ABO blood group incompatibility, HDFN and, 266-269
Abortion controversy, fetal pain perception and, 276-277
ACE inhibitors, 343
Actinetobacter spp., multidrug resistant, 27-28
Acupuncture, 320-321
Acyclovir
  for neonatal HSV infections, 19, 21
  oral, for HSV suppression, 23
  pretherapy specimens, 21
Addiction, to pain medication, 319

AUTHOR INDEX

Adler, S.P., 10
Allen, R.H., 185
Almgren, C., 318
Anand, K.J.S., 273, 275, 283, 309, 318
Ananth, C.V., 196
Andiman, W.A., 112

Baltimore, R.S., 1, 33
Beardsley, D.S., 203, 250
Belfort, M.A., 135
Bhutta, A.T., 303
Bianchi, B., 223
Bizzarro, M.J., 26
Bonanno, C., 348
Bottalico, J.N., 176
Boyle, E., 289
Brancazio, L.R., 167
Brown, H., 167
Buonanno, F.S., 243

Carbajal, R., 309
Chapman, R.L., 39
Coustan, D.R., 363

D'Alton, M.E., 331
Denne, S.C., 56
Dildy III, G.A., 135
Douglas, N.C., 332
Dove, L., 348

Ebcioglu, Z., 339
Eble, B., 309
Ehrenkranz, R.A., 47, 48
Erez, O., 142
Espinoza, J., 142
Estes, C.M., 372

Fitzgerald, M., 298
Fuchs, K.M., 331, 339, 363

Gallagher, P.G., 26, 254
Ghidini, A., 232
Golianu, B., 318
Gotsch, F., 142
Grabowski, E.F., 243
Greer, F.R., 89
Grotegut, C.A., 167
Gurewitsch, E.D., 185

Hall, R.W., 273, 275, 289
Hardman, M.P., 275
Hassan, S.S., 142
Hossain, N., 208, 240

Infante-Rivard, C., 213

James, A.H., 167
Jenson, H.B., 1
Johnson, T.L., 185
Johnston, C.C., 283

Kaminsky, L., 126
Kashyap, S., 74
Kennedy, K.A., 61
Kilpatrick, S.J., 159
Kimberlin, D.W., 19
Kinzler, W.L., 126
Kocoshis, S.A., 104
Kominiarek, M.A., 159
Krane, E., 318
Krishnamoorthy, K , 243
Kusanovic, J.P., 142

Langhoff-Roos, J., 219
Lehr, V.T., 323
Lowery, C.L., 275
Lucke, J.F., 61
Lykke, J.A., 219

Manning, N., 275
Marks, P.W., 227
Mazaki-Tovi, S., 142
Mecacci, F., 223
Meek, J., 298
Mittal, P., 142
Morales, Y., 83
Moyer-Mileur, L.J., 96

Nigro, G., 10

Paidas, M.J., 203, 208, 219, 223, 232
Paintsil, E., 112
Patrizio, P., 204, 232
Pedroza, C., 61
Pereira, L., 10
Pieralli, A., 223
Pineles, B.L., 142
Poindexter, B.B., 47, 56

Ranger, M., 283
Ratner, L.E., 331
Restaino, S., 354
Ricci, S., 232
Romero, R., 142

Sauer, M.V., 332
Schanler, R.J., 83
Schelonka, R.L., 2
Seybold, J., 318
Shah, M., 332
Slater, R., 298
Smulian, J.C., 125, 135
Stack, G., 262
Steiner, L.A., 254

Taddio, A., 323
Than, N.G., 142
Tortoli, P., 232
Triche, E.W., 240
Tyson, J.E., 61

Urban, G., 232

Vergani, P., 232
Vitiello, D., 204

Waites, K.B., 2
Wessel, J.J., 104
Westhoff, C., 372
Wilt, J., 354
Wu, D.W., 339, 354
Wu, Y., 262

Young, B., 219
Young, T., 289

SUBJECT INDEX

Aase syndrome, 259
Abdominal skin reflexes (ASR), 285-286
ABO blood group incompatibility, HDFN and, 266-269
Abortion controversy, fetal pain perception and, 276-277
ACE inhibitors, 343
Actinetobacter spp., multidrug resistant, 27-28
Acupuncture, 320-321
Acyclovir
  for neonatal HSV infections, 19, 21
  oral, for HSV suppression, 23
  pretherapy specimens, 21
Addiction, to pain medication, 319

Adhesion, embryonic, 205
Adverse pregnancy outcomes
  autoimmune disorders, 223-226
  cardiovascular disease, long-term, 219-221
  environmental factors, 240-242
  future research directions, 210-211
  inherited thrombophilia and, 209-210
  prevention strategies, 210
  thromboembolism, 227-230
  uteroplacental interface and, 208-209
African-American women, recurrent spontaneous preterm birth and, 147
Air pollution, adverse pregnancy outcome and, 241
Alkaline phosphatase, 101-102
Allograft loss, risk in pregnant renal transplant recipients, 340-341
Alloimmune thrombocytopenia, fetal and neonatal, 269-270
Amino acid infusions, parenteral
  for ELBW infants, evidence-base for, 56-60
  for VLBW infants, evidence base for, 51-53
Amphotericin B, for neonatal *Candida* infections, 40-41
Analgesia
  with ketamine, 305
  for ventilated neonates, 289-290
Anemias, in premature infants, 102
Anesthesia. *See also* Topical anesthetics
  for heart transplant recipients, 357
  with ketamine, 305
  local, 323-324
Anesthetics
  inhalation, adverse pregnancy outcome and, 241
Aneuploidy, fetal growth restriction and, 126-127
Angiotensin converting enzyme inhibitors, 343
Anthropometric assessment, of VLBW infant, 96-100
Antiangiogenic factors, 208-209
Antibiotic prophylaxis, for heart transplant recipients, 357-358
Antibiotic-resistant organisms, in NICU, 26-30
Antibiotic susceptibility, intrapartum prophylaxis of GBS infections and, 37
Anti-CMV IgG testing, 11
Anticoagulation
  complications of, 230
  delivery and, 229-230
  with heparin (*See* Heparin; Low-molecular weight heparin)
  postpartum, 230
  prophylactic, for thromboembolism in pregnancy, 227-228
  therapeutic, during pregnancy, 170-172, 228-229
  with warfarin, 252
Antifungal therapy
  for neonatal *Candida* infections, 40-42
  prophylaxis, for *Candida* infection, 42-43
Antihypertensive therapy, for pregnant renal transplant recipients, 343-344
Antimetabolic agents, 365
Antiphospholipid antibodies (aPL), 224, 245
Antiphospholipid antibody syndrome, 131, 224
Antiretroviral therapy, suppressive, for HSV, 23
Antithrombin III, 244-245
Antitretroviral therapy, for HIV+ mothers, 114
Antiviral therapy, for herpes simplex infections, 19
aPL (antiphospholipid antibodies), 224, 245
Apoptosis, in pulmonary inflammation and injury, 4
ART (assistive reproductive technology), for solid organ transplant recipients, 334-336
Arterial ischemic stroke. *See* Stroke, perinatal
Arterial puncture, topical anesthesia for, 324-325
Asparate amino transaminase (AST), 101
Aspirin
  for adverse pregnancy outcome prevention, 210
  FGR risk reduction and, 131
ASRs (abdominal skin reflexes), 285-286
Assistive reproductive technology (ART), for solid organ transplant recipients, 334-336
AST (asparate amino transaminase), 101
Autoimmune disorders, 223-226
  rheumatoid arthritis, 225
  scleroderma, 225
  Sjogren syndrome, 225-226
  systemic lupus erythematosus, 223-225
Azathioprine, 365, 368-369

Bacterial vaginosis, treatment of, 151
Barrier contraceptive methods, for transplant recipients, 375-376
Benzodiazepines, for ventilated preterm infants, 293, 295
Biases, in studies of recurrence, 198-199
Blood bank testing, perinatal, 263
Blood product replacement, in perinatal period, 262-270
  adverse outcomes, 265-266
  fetal and neonatal alloimmune thrombocytopenia, 269-270
  hemolytic disease of the fetus and newborn, 266-269
  plasma/cryoprecipitate transfusion, 265
  platelet transfusion, 265
  RBC transfusion, 263-265
  special considerations/modifications, 265
Blood sampling, topical anesthetics for, 324-325, 327-328
Blood urea nitrogen (BUN), 100-101
"Blueberry muffin syndrome," 16
Body composition assessment, of VLBW infant, 99-100
Body weight, of VLBW infant, 96-97
Breastfeeding
  for heart transplant recipients, 358
  immunosuppressive drugs and, 368-369
  by lung transplant recipients, 361
  for pain management, 319-320
Bronchopulmonary dysplasia (BPD)
  effect of early nutrition management on, 52-53
  etiology of, 2
  future research on *Ureaplasmas*, 7
  impact of *Ureaplasma* infection treatment on, 6-7
  Ureaplasma and, 4-6
BUN (blood urea nitrogen), 100-101

Calcineurin inhibitors, 366
Calcium
  in preterm infant formulas, 79
  requirements, for VLBW infants, 76-77
Calcium channel blockers, 343
Candida infections, neonatal, 39-44
  diagnosis, 40
  epidemiology, 39-40
  prevention, 42-44
  treatment, 40-42
Carbohydrates
  in preterm infant formulas, 79
  requirements for VLBW infants, 76
Cardiovascular disease
  preeclampsia and, 220
  risks, for pregnant heart transplant recipients, 355-356
Case-control studies, of SGA infants, 215-216
Catch-up growth, 93-94
Centeral catheters
  topical anesthetics for, 325-326
Central catheters
  thrombosis-associated with, 251-252
Central nervous system disease, HSV, 20
Cerclage, cervical, 151
Cervical caps, for transplant recipients, 375-376
Cervical insufficiency, recurrent spontaneous preterm birth and, 146-147
Chemokines, 205
Cholestasis, TPN-associated, 105-106
Choriamnionitis, *Ureaplasma* infections and, 3
Chromosomal aberrations, fetal growth restriction and, 126-127

Chronic villitis of unknown etiology, 128
CH50 titers, 224
Circumcision, topical anesthetics for, 326-327
Clinical study designs, for studying recurrence in pregnancy, 197-198
Coagulation disorders, recurrent postpartum hemorrhage and, 162-163
Combination therapy
  hormonal contraceptives, for transplant recipients, 374-375
  for neonatal *Candida* infections, 42
Compound prothrombotic conditions, arterial ischemic stroke and, 245
Confounding, 198
Congenital dyserythropoietic anemia, 259
Congenital heart block, 225
Congenital infections, fetal growth restriction and, 127
Congenital neonatal pneumonia, *Ureaplasma* and, 3-4
Congenital thrombophilic traits, 251
Connective tissue disorders, recurrent postpartum hemorrhage and, 163
Contraception, for transplant recipients, 372-376
Copper, 106
Cord blood testing, 263
Cortical recordings, in assessing neonatal pain, 300
Cyclophosphamide, 366
Cyclosporin, 366
Cytokines, 205
Cytomegalovirus infections (CMV), 10
  congenital
    fetal outcomes, 11
    hemochorial human placenta development and, 14
    maternal neutralizing antibodies and, 15
    placental dysfunction and, 16
    postnatal therapy, 13-14
    prenatal therapy, 12-13
    replication, cytotrophoblasts and, 15
    risk factors, 11
    symptoms, 11
  maternal
    natural history of, 10-11
    prevention during pregnancy, 11-12
    primary, 16
  vertical transmission, 11-12
Cytotrophoblasts, 14, 15

Danish National Birth Cohort (DNBC), 220-221
Dehydrated hereditary stomatocytosis (DHST), 258
Delivery, timing/mode, for pregnant renal transplant recipients, 344
Depot medroxyprogesterone acetate (DMPA; DepoProvera®), for transplant recipients, 373-374
DHST (dehydrated hereditary stomatocytosis), 258
Diabetes mellitus
  maternal, fetal growth restriction and, 128
  prevention in women with previous GDM, 183
Diamond-Blackfan anemia, 258
Diaphragms, for transplant recipient contraception, 376
Distraction techniques, for pain management, 319
DMPA (depot medroxyprogesterone acetate), for transplant recipients, 373-374
DNBC (Danish National Birth Cohort), 220-221
DNPB (dorsal penile nerve block), 326-327
Doppler ultrasound velocimetry
  effect of gestational age on, 233-235
  of uteroplacental circulation, 232-233
Dorsal penile nerve block (DNPB), 326-327
3-D power Doppler ultrasound, 236-237
Drug use, during pregnancy
  immunosuppressants (*See* Immunosuppressant drugs)
Drug use, in pregnancy
  FDA risk categories for, 364
  fetal-maternal circulation and, 364-365
  fetal metabolism of, 364-365

Echinocandins, for neonatal *Candida* infections, 41-42
Eclampsia, preeclampsia recurrence after, 137
EIA testing, for HIV-1, 113
ELBW. *See* Extremely low birth weight infants
Elliptocytosis, hereditary, 258
Embden-Meyerhof pathway, 256
Embryonic development, 204-206
EMLA, 324
Endometrium, proliferation/maturation of, 204
Energy
  in preterm infant formulas, 78-79
  requirements, for VLBW infants, 74-76
Enteral feedings, for high-risk infants
  Bayesian analyses, 70-72
  clinical trial design considerations, 65-69
  evidence base for, 51-53
  initiation, 61-63
  macronutrient requirements
    for ELBW infants, 79-80
    for VLBW infants, 74-77
  methodological problems, 64-65
  monitoring, laboratory tests for, 100-102
  NEC or death incidence and, 65-66, 72
  regimens
    description of, 65, 69-70
    for VLBW infants, 77-79
  with short bowel syndrome, 107-109
  volume increases, 64
  vs. trophic feedings, 63-64, 65, 66
Enterobacter spp., multidrug resistant, 27-28
Environmental factors
  in adverse pregnancy outcomes, 240-242
  for pain management, 320
Erythrocyte disorders, 254-259
  hemoglobin-related, 255-256
  membrane-related, 257-258
  metabolic, 256-257
  production-related, 258-259
Erythrocytes, neonatal, 254-255
Escherichia coli infections
  early-onset, 36-37
  multidrug resistant, 27-28
Etonorgestrel implant, for transplant recipients, 374
Extremely low birth weight infants (ELBW)
  definition of, 56
  early protein losses and, 57-58
  growth restriction and, 56-57
  macronutrient requirements for, 79-80
  parenteral amino acid infusions for, 56-60

Facilitated tucking, 319
Factor V Leiden, 214, 215
  arterial ischemic stroke and, 244
  congenital thrombophilic traits and, 251
  small-for-gestational age infants and, 214, 215
Fanconi's anemia, 259
Fat
  in preterm infant formulas, 79
  requirements, for VLBW infants, 76
Fentanyl, for ventilated preterm infants, 293
Fertility
  disorders
    in liver transplant recipients, 333-334
    in renal transplant recipients, 332-333
  liver transplant recipients and, 348-349
Fetal and neonatal alloimmune thrombocytopenia (FNAIT), 269-270
Fetal growth restriction (FGR)
  evaluation of, 128-129
  fetal causes of, 126-127

Fetal growth restriction (FGR) (*Continued*)
future research, 132
maternal causes of, 128-130
placental causes of, 127-128
recurrent, prevention of, 129-132
risk, for subsequent pregnancies, 129
Fetal hemoglobin (HbF), 254-255
Fetus
exposure to immunosuppressive drugs, 365-367
growth assessment, 192
immunologic alterations after in utero exposure to immunosuppressive drugs, 366
monitoring, for pregnant renal transplant recipients, 344
pain, neurodevelopmental changes, 275-280
risks
with maternal heart transplant recipients, 357
in pregnant lung transplant recipients, 361
FGR. *See* Fetal growth restriction
Fibroids, recurrent postpartum hemorrhage and, 161-162
Fluconazole
for *Candida* infection prophylaxis, 42-44
for treatment of neonatal *Candida* infections, 41
Flucytosine, for neonatal *Candida* infections, 41
FNAIT (fetal and neonatal alloimmune thrombocytopenia), 269-270
Fondaparinux, 171
Formulas
for preterm infants after discharge, 90, 91-92
for VLBW infants, 77-79
Fortification, of human milk, 84

Ganciclovir
for postnatal CMV therapy, 13-14
for prenatal CMV therapy, 12
GBS. *See* Group B streptococcal infections
GDM. *See* Gestational diabetes
Genetic association studies, of SGA infants, 215-216
Genetic-conflict hypothesis, 138-139
Genetic hypothesis, of preeclampsia recurrence, 138
Genetic linkage study, adverse pregnancy outcomes, 221
Genetics counseling, for pregnant renal transplant recipients, 342
Gestational age determination, 277-278
Gestational diabetes (GDM)
definition of, 176
diagnosis of, 179
future research directions, 183
glucose tolerance status and, 180-181
management, 179-180
postpartum and long-term management, 181-182
prevention of diabetes and, 183
recurrence, 176-183
epidemiology of, 176-178
management of, 179-180
prevention of, 180
risk factors for, 178, 179
β-Globin chain defects, 255-256
Glucocorticoids, 344, 365
Glucose-6-phosphate dehydrogenase deficiency (G6PD), 256-257
Glucose tolerance, gestational diabetes and, 179, 180-181
Glutathione-S-transferases (GSTs), 214
G6PD (glucose-6-phosphate dehydrogenase deficiency), 256-257
Gram-negative rods, multidrug resistant, 27-28
Group B streptococcal infections (GBS), 33-37
antibiotic susceptibility, intrapartum prophylaxis and, 37
ecology of sepsis, intrapartum prophylaxis and, 35-37
prevention, historical perspective on, 33-35
rate, intrapartum prophylaxis and, 35
Growth
charts, for VLBW infant, 97-99
concerns for preterm infants, 93-94
postnatal, 48-50
GSTs (glutathione-S-transferases), 214

HAART, 118
HDFN. *See* Hemolytic disease of the fetus and newborn
Head circumference, of VLBW infant, 97
Heart block, congenital, 225
Heart-lung transplant recipients, fertility/reproductive disorders in, 334
Heart transplant recipients
fertility/reproductive disorders in, 334
fetal risks, 357
intrapartum care, 357-358
postpartum care, 358
preconception counseling, 354-355
prenatal care, 355-357
Heel lance, topical anesthetics for, 327-328
HELLP syndrome, preeclampsia recurrence and, 135-137
Hemochorial human placenta development, congenital CMV and, 14
Hemoglobin, fetal, 254-255
Hemoglobin disorders, 255-256
Hemoglobin variants, unstable, 256
Hemolytic disease of the fetus and newborn (HDFN), 266-269
description, 266
etiologic antibodies, 266-267
laboratory diagnosis, 267-268
laboratory monitoring, 268-269
transfusion therapy, 269
Heparin
for adverse pregnancy outcome prevention, 210
low-molecular weight (*See* Low-molecular weight heparin)
thrombocytopenia-induced by, 252
unfractionated, for neonatal venous thromboembolism, 252
use during pregnancy, 170-171
Hereditary elliptocytosis, 258
Hereditary pyropoikilocytosis, 258
Hereditary spherocytosis, 257-258
Hereditary stomatocytosis syndromes, 258
Herpes simplex infections, neonatal, 19-24
acquisition, timing of, 20
Cesarean delivery and, 23
clinical presentation, 20
differential diagnosis, 20-21
evaluation, 21
follow-up, 23
incidence, 20
oral acyclovir suppressive therapy, 23
pretreatment specimens, 21
prognosis/outcome, 21-23
treatment, 19, 21
HIG
for CMV infection, 16
for prenatal CMV therapy, 12-13
HIV-1, 112-122
antiretroviral therapy, postnatal management, 118-119
antitretroviral therapy for HIV+ mothers, 114-116
antitretroviral therapy for HIV+ pregnancy, 114-116
counseling, for pregnant women, 113-114
counseling/testing for, 113-1114
different methods for resource-rich and resource-limited settings, 114-116
intervention during pregnancy, 116-121
mother-to-child transmission, 116
pregnancy with high risk of contracting HIV, 119-120
screening tests, 113-114
seroconversion during pregnancy, 120-121
vertical transmission, risk reduction strategies for, 112-116

HIV-exposed infants, well baby care for, 118-122
Hospital-associated infections, MRSA, 27
Host defense mechanisms, human milk and, 84-85
HPO (hypothalamic-pituitary-ovarian axis), abnormalities, 332-333
Human milk
  donor, 86-87
  effects on host defense, 84-85
  fortification of, 84
  fortified, for VLBW infants, 77
  for high-risk infants, 69
  neurodevelopmental outcome and, 85-86
  for preterm infants after discharge, 92-93
  unfortified, 83-84
Hyperdynamic disease hypothesis, 138
Hyperhomocysteinemia, 245
Hypertension, maternal
  fetal growth restriction and, 128
  in heart transplant recipients, 356-357
  in lung transplant recipients, 360
  in renal transplant recipients, 340
Hypothalamic-pituitary-ovarian axis (HPO), abnormalities, 332-333
Hypoxia, at maternal-fetal interface, 14

IFALD (intestinal failure-associated liver disease), 105
IGFs (insulin-like growth factors), 101
Immune/immunogenetic maladaptation hypothesis, 138
Immunosuppressive drugs, 363-369
  breastfeeding and, 368-369
  drug risk categories, 364
  monitoring during pregnancy, 368
  in utero exposure, 365-367
    developmental outcomes after, 366-367
    immunologic alterations after, 366
    pregnancy outcomes, 367-368
Implantation
  adhesion and, 205
  future research, 206
  stages of, 204-205
Infant biometry, in shoulder dystocia, 188-190
Infections, maternal
  cytomegalovirus (*See* Cytomegalovirus, maternal)
  in heart transplant recipients, 356
  in lung transplant recipients, 360
  primary *vs.* recurrent, 10-11
  in renal transplant recipients, 341
  risk factors, 11
Inhalation anesthetics, adverse pregnancy outcome and, 241
Inherited thrombophilia, adverse pregnancy outcome risk and, 209-210
Insulin-like growth factors (IGFs), 101
Integrins, 205
Interleukins, 4
Interuterine growth charts, 97-99
Intestinal failure, *vs.* short bowel syndrome, 104-105
Intestinal failure-associated liver disease (IFALD), 105
Intracranial hypertension, from ketamine, 306
Intrapartum care, heart transplant recipients, 357-358
Intrauterine devices (IUDs), for transplant recipients, 372-373
Intrauterine growth restriction (IUGR)
  likelihood ratio, 209-210
  measurement standards, 213
  renal transplant recipients and, 341-342
  risk, in pregnant renal transplant recipients, 340
Intravenous cannulation, topical anesthetics for, 325
Intravenous immunoglobulin (IVIG), for adverse pregnancy outcome prevention, 210
Itraconazole, for neonatal *Candida* infections, 41
IUDs (intrauterine devices), for transplant recipients, 372-373
IUGR. *See* Intrauterine growth restriction

Ketamine
  adverse effects, 305-306
  analgesia, 305
  anesthesia/sedation, 305
  clinical applications, 305
  historical perspective, 303
  mechanisms of action, 304-305
  pharmacology, 303-304
Klebsiella spp., multidrug resistant, 27-28

Labetolol, 343
Laboratory assessment, of VLBW infants, 100-102
Laryngoscopy, adverse physiological effects, 312, 315
Lead exposures, adverse pregnancy outcome and, 240-241
Leflunomide, 366
Length, of VLBW infant, 97
Leptin, 101
Lidocaine
  liposomal, 327
  for neonatal anesthesia, 323-324
Lidocaine-prilocaine, 324-325
Lipid emulsions, for VLBW infants, evidence base for, 51-53
Lipoprotein(a), 244
Literature review, on pregnancy outcomes for liver transplant recipients, 350
Liver transplant recipients
  fertility and, 348-349
  fertility/reproductive disorders in, 333-334
  pregnancy management recommendations, 352-353
  pregnancy outcomes for, 349-352
  timing of pregnancy and, 349
LMWH. *See* Low-molecular weight heparin
Local anesthesia, 323-324
Lorazepam, for ventilated preterm infants, 294
Low-birth weight infants. *See* Extremely low birth weight infants; Very low birth weight infants
  of heart transplant recipients, 357
Low-molecular weight heparin (LMWH)
  complications of, 230
  for neonatal venous thromboembolism, 252
  for postpartum anticoagulation, 230
L-selectin, 205
Lumbar puncture, topical anesthetics for, 326
Lung transplant recipients
  fertility/reproductive disorders in, 334
  pregnancy of, 358-361

Macronutrient requirements
  for ELBW infants, 79-80
  for VLBW infants, 74-77
Male condom, for transplant recipients, 375
Malnutrition, maternal, fetal growth restriction and, 128
Manganese, 106
Massage, for pain management, 320
Maternal factors, in fetal growth restriction, 128-130
Maternal-fetal interface, hypoxia, 14
Maternal floor infarct, 127
Maternal outcomes, for pancreatic transplant recipient pregnancies, 345
Mechanical ventilation, for preterm neonates
  adverse effects from, 290, 291
  knowledge gaps, 294
  non-medical management, case for, 290-292
  pharmacologic treatment, 292-294
Menstrual dysfunction, with liver disease, 333-334
Meperidine, for ventilated preterm infants, 293
Metabolic syndrome, as pre-diabetic risk factor, 178
Metal exposures, adverse pregnancy outcome and, 240-241
Methicillin-resistant *Staphylococcus aureus* (MRSA), 26-27
Methyldopa, 343
MGDA (multigate spectral Doppler analysis), 237-238

Midazolam, for ventilated preterm infants, 293-294
Mode of delivery
  for heart transplant recipients, 357
  in pregnant lung transplant recipients, 361
Morbidity, HSV infections, neonatal, 22-23
Morphine, for ventilated preterm infants, 291, 292-293
Mortality, HSV infections, neonatal, 21-22
Mother-to-child transmission, HIV-1, 116
MRSA (methicillin-resistant *Staphylococcus aureus*), 26-27
MTHFR A1298C variant, 214, 215
MTHFR C677T polymorphism, 170, 245
MUC1 (mucin-rich glycoprotein), 205
Multigate spectral Doppler analysis (MGDA), 237-238
Multiple gestations, preeclampsia recurrence after, 137-138
Multivariable *vs.* multivariate, 199
Mycophenolate, 365

nAChRs (nicotinic acetylcholine receptors), 304
National Transplant Pregnancy Registry (NTPR), 349-350
Near-infrared spectroscopy (NIRS), 286, 300
Necrotizing enterocolitis (NEC)
  early feeding and, 62
  effect of early nutrition management on, 52-53
  human milk feeding and, 84-85
Neonatal infections. *See specific neonatal infections*
Neonatal intensive care unit (NICU), antibiotic-resistant organisms in, 26-30
NEOPAIN Trial, 291
Neurodevelopmental outcome, human milk and, 85-86
Neuronal pathways, development of, 277-279, 299
Neurotoxicity, of ketamine, 306
Nicotinic acetylcholine receptors (nAChRs), 304
Nifedipine, 343
NIRS (near-infrared spectroscopy), 286, 300
NMDA receptor antagonist. *See* Ketamine
Nociception
  definition of, 277
  pain perception and, 298-301
Nonaneuploid genetic syndromes, fetal growth restriction and, 127
Nonnucleoside reverse-transcriptase inhibitors (NNRI), 118
Nonnutritive sucking, for pain management, 319
Non-pharmacologic therapies, for pain management, 319-321
Noxious stimuli, autonomic and endocrine responses to, 279-280
Nutritional management
  breast milk (*See* Human milk)
  enteral (*See* Enteral feedings)
  in HIV-1 (*See* HIV-1)
  post-discharge (*See* Post-discharge nutrition, for preterm infants)
  of short bowel syndrome (*See* Short bowel syndrome)
  of VLBW infants, 48-54
    early parental/enteral management, evidence basis for, 51-53
    parenteral amino acid infusions (*See* Amino acid infusions, parenteral)
    postnatal growth studies and, 48-50
    recommendations, evidence-based, 53-54
    variations in, effects on growth outcome, 50-51
NuvaRing®, for transplant recipients, 375
Nystatin, for *Candida* infection prevention, 42-43

Obstetrical outcomes, for pancreatic transplant recipient pregnancies, 344-345
OHST (overhydrated hereditary stomatocytosis), 258
Opioids, for ventilated preterm infants, 292
Oral contraceptives, for transplant recipients, 374-375
Organic solvents, adverse pregnancy outcome and, 241
Ortho Evra®, for transplant recipients, 375
Overhydrated hereditary stomatocytosis (OHST), 258

Pain
  assessment, neonatal, 299-301
    age differences in response to pain, 284-285
    controversies, 283-287
Pain (*Continued*)
    cortical activations and, 286
    flexion reflexes with procedural pain, 285-286
    future research directions, 287
    measurement standards for, 286-287
    prolonged *vs.* acute, 285
  definition of, 275-276, 283-284
  epidemiology in infants, 323
  exposure, long-term developmental impacts of, 280
  expression, age differences in, 284-285
  fetal, neurodevelopmental changes and, 275-280
  local anesthesia, 323-324
  management
    acupuncture for, 320-321
    graduated multidisciplinary approach, 321
    non-pharmacologic, 319-321
    for ventilated neonates, 289-295
  perception
    with emotional reaction, 277-279
    during fetal/neonatal development, 276
    neuronal pathways, development of, 277-279, 299
    nociception and, 298-301
  physiological *vs.* behavioral responses to, 284-285
Pain medication
  addiction, 319
  physiologic dependence, 319
  tolerance, 318-319
  withdrawal, 318-319
Pancreas-kidney transplant recipients, 334
Pancreatic transplantation, pregnancy after, 344-345
PAPP-A (pregnancy associated plasma protein A), 209
Parenteral nutrition
  amino acid infusions (*See* Amino acid infusions, parenteral)
  monitoring, laboratory tests for, 100-102
  for short bowel syndrome, 105-107
  for VLBW infants, evidence base for, 51-53
Parent-of-origin effects, SGA infants and, 216-217
PCR (polymerase chain reaction), 19, 21
Pearson syndrome, 259
Pectin, for enteral nutrition formulas, 107-108
Pelvimetry, of shoulder dystocia, 188-190
Perinatal period, blood product replacement in. *See* Blood product replacement, in perinatal period
Peripartum cardiomyopathy (PPCM), 355
Peripherally inserted central catheters (PICC)
  thrombosis-associated with, 251-252
  topical anesthetics for, 325-326
Pesticide exposure, adverse pregnancy outcome and, 241
Phosphorus, in preterm infant formulas, 79
Phosphorus requirements, for VLBW infants, 76-77
Physical stress, adverse pregnancy outcome and, 241
Physiologic dependence, to pain medication, 319
PICC. *See* Peripherally inserted central catheters
PIPP (premature infant pain profile), 300-301, 325
Placenta
  abnormalities
    causing FGR, 127-128
    preeclampsia recurrence and, 138
  changes, during pregnancy stages, 208-209
  damage from congenital CMV infection, 16
  lesions, in adverse pregnancy outcome, 209
  maternal neutralizing antibodies, congenital CMV and, 15
  pathology, perinatal stroke and, 247
  retained, recurrent postpartum hemorrhage and, 162
  size, primary CMV maternal infection and, 16
Placental cord insertion, sonography, in evaluating FGR risk, 130-131
Placenta-mediated pregnancy complications, 219-220
Plasma/cryoprecipitate transfusion, perinatal, 265
Plasminogen activator inhibitor-1, 245

Platelet transfusion, perinatal, 265
Polymerase chain reaction (PCR), 19, 21
Post-discharge nutrition, for preterm infants, 89-94
  formulas for, 90, 91-92
  goals of, 89-90
  growth concerns, 93-94
  human milk, 92-93
  specific nutrient requirements, 90-91
Postpartum care
  heart transplant recipients, 358
  pregnant lung transplant recipients, 361
Postpartum hemorrhage (PPH), 159-164
  etiology of, 159-160
  late or secondary, 159
  prevalence, 159
  recurrence
    condition-specific risks for, 161-163
    epidemiology of, 160-161
    future research directions, 164
    prevention of, 163-164
  risk factors, 159, 160
Postthrombotic syndrome (PTS), 252-253
PPCM (peripartum cardiomyopathy), 355
Preconception counseling
  for heart transplant recipients, 354-355
  for lung transplant recipient pregnancies, 358-359
  for pancreatic transplant recipient pregnancies, 345
  for pregnant renal transplant recipients, 342
Preeclampsia
  long-term cardiovascular disease and, 220
  perinatal stroke and, 245-246
  placental changes, 208
  prediction, uterine artery Doppler ultrasound for, 235-236
  in pregnant heart transplant recipients, 356-357
  in pregnant lung transplant recipients, 360
  in pregnant renal transplant recipients, 340
  recurrence, 135-140
    after eclampsia, 137
    after HELLP syndrome, 135-137
    after multiple gestations, 137-138
    clinical features of, 138
    epidemiology of, 135-137
    future research directions, 140
    pathogenesis, 138-139
    prevention of, 139-140
    risk, evaluation/management of, 139
  risk factors, 135
  severe, 209
Pregnancy
  adverse outcomes (*See* Adverse pregnancy outcomes)
  after heart transplantation, 354-358
  after lung transplantation, 358-361
  after pancreatic transplantation, 344-345
  complications
    postpartum hemorrhage, 159-164
    recurrent gestational diabetes, 176-183
    thromboembolism, 167-173
  exposure and end points, defining, 197
  loss, renal transplant recipients and, 341
  management
    for liver transplant recipients, 352-353
    for pancreatic transplant recipients, 345
    for renal transplant recipients, 342-344
  outcomes
    after in utero exposure to immunosuppressive drugs, 367-368
    for liver transplant recipients, 349-352
  pathology in, 206
  perinatal HIV infection interventions, 116-121
  pulmonary functions in, 359
Pregnancy (*Continued*)
  recurrent events, epidemiologic approaches for, 196-200
  risk behaviors for STDs, 112-113
  timing
    for heart transplant recipients, 354-355
    for liver transplant recipients, 349
    for lung transplant recipients, 358-359
Pregnancy associated plasma protein A (PAPP-A), 209
Pregnant organ transplant recipients
  after liver transplantation (*See* Liver transplant recipients)
  after thoracic organ transplantation (*See* Heart transplant recipients; Lung transplant recipients)
  immunosuppressant therapy, 363-369
  in renal transplant recipients (*See* Renal transplant recipients)
Premature infant pain profile (PIPP), 300-301, 325
Premature ovarian failure, 333
Premature rupture of membranes (PROM), 144-145
Premedication, for tracheal intubation. *See* Tracheal intubation, premedication
Prenatal care
  for lung transplant recipients, 359
  for pregnant renal transplant recipients, 342-343
Preterm birth
  definition of, 142-143
  perinatal morbidity/mortality and, 142
  recurrent, 143-152
    cerclage, as treatment for, 151
    definition of, 143
    prevention of, 149-151
    treatment of bacterial vaginosis and, 151
  recurrent indicated, 149
  recurrent spontaneous, 143-148
    additional risk factors, 147-148
    African-Americans and, 147
    cervical insufficiency and, 146-147
    frequency of, 143-144
    premature rupture of membranes, 144-145
    twin gestation and, 145-146
    vs. recurrent indicated, 149
  renal transplant recipients and, 341-342
  in SLE pregnancy, 224
Preterm infants. *See also* Small-for-gestational-age infants
  anemias in, 102
  development of BPD, *Ureaplasma* and, 4-6
  of heart transplant recipients and, 357
  post-discharge nutrition (*See* Post-discharge nutrition, for preterm infants)
  postnatal growth studies, 48-50
  Ureaplasma infections and, 3
  ventilated (*See* Mechanical ventilation, for preterm neonates)
Progesterone administration, for prevention of recurrent preterm birth, 149-151
Progestin-only pills, for transplant recipients, 375
PROM (premature rupture of membranes), 144-145
Protein
  loss, postnatal, 57-58
  requirements, for VLBW infants, 74-76
Protein, in preterm infant formulas, 78-79
Protein C, 244-245, 251
Protein S, 244-245, 251
Prothrombin 20210A, 244
Pseudomonas aeruginosa, multidrug resistant, 27-28
Psychomimetic effects, of ketamine, 306
Pyropoikilocytosis, hereditary, 258
Pyruvate kinase deficiency, 256

RA (rheumatoid arthritis), 225
Radiation exposure, adverse pregnancy outcome and, 241
Rapid test, for HIV-1, 113-114

RBC transfusion, perinatal, 263-265
Renal transplant recipients
  fertility/reproductive disorders in, 332-333
  maternal pregnancy complications, 339, 340-341
  obstetric/fetal outcomes, 341-342
  recommendations for pregnancy management, 342-344
  risk of maternal infections during pregnancy, 341
  spontaneous pregnancies, 339
Reproductive disorders
  in liver transplant recipients, 333-334
  in renal transplant recipients, 332-333
Rh blood group incompatibility, HDFN and, 266-269
Rheumatoid arthritis (RA), 225

Scleroderma, 225
Sedation
  with ketamine, 305
  for ventilated neonates, 289-290
SEM (skin, eyes, and/or mouth disease), 20
Serology testing
  anti-CMV IgG, 11
  HSV infection, 21
Serum glutamic oxaloacetic transaminase (SGOT), 101
Sexually transmitted infections, HIV-1 status and, 112-113
SGA infants. *See* Small-for-gestational-age infants
SGOT (serum glutamic oxaloacetic transaminase), 101
Short bowel syndrome, 104-109
  causes of, 104-105
  enteral nutrition for, 107-109
  parental nutrition for, 105-107
  therapy goals for, 105
  vs. intestinal failure, 104-105
Shoulder dystocia, 185-193
  documentation, 186-187
  follow-up of infant status, 191
  maternal risk factors, preconceptual management of, 191-192
  pathogenesis of, 185-186
  patient counseling, 190-191
  pelvimetric evaluation, 188-190
  recurrence
    antenatal management in subsequent pregnancy, 192-193
    anticipation of, 193
    prevention of, 186-191
  relating delivery details to pathophysiology, 187-188
  risk, 185
Shwachman-Diamond syndrome, 258-259
Sirolimus, 366
Sjogren syndrome, 225-226
Skin, eyes, and/or mouth disease (SEM), 20
Skin-to-skin contact, for pain management, 319
Small-for-gestational-age infants (SGA infants)
  definition of, 126
  genetic association studies, 215-216
  genetic pathways, 213-214
  parent-of-origin effects, 216-217
  thrombophilia and, 214
  xenobiotic-metabolizing genes and, 214-215
Smoking, adverse pregnancy outcome and, 240
Solid organ transplant recipients
  assistive reproductive technology for, 334-336
  fertility/reproductive disorders in, 332-334
  pregnancy in (*See under specific types of solid organ transplants*)
Spherocytosis, hereditary, 257-258
Stillbirth, pregnancy in heart transplant recipients and, 357
Stress, adverse pregnancy outcome and, 241-242
Stress response, 279
Stroke, perinatal, 243-248
  antiphospholipid antibodies and, 245
  antithrombin III and, 244-245
Stroke, perinatal, 243-248 (*Continued*)
  causes of, 243
  clinical diagnosis/triage, 246-247
  clinical management, 247-248
  cognitive and motor function, long-term, 248
  compound prothrombotic conditions, 245
  diagnostic imaging, 246-247
  Factor V Leiden and, 244
  hyperhomocysteinemia and, 245
  incidence, 243
  lipoprotein(a) and, 244
  maternal-fetal thrombophilia interactions and, 245-246
  maternal preeclampsia and, 245-246
  MTHFR polymorphisms and, 245
  placental pathology and, 247
  plasminogen activator inhibitor-1 and, 245
  proteins C and S, 244-245
  prothrombin 20210A and, 244
  risk factors, 243
  thrombophilia and, 244
  thrombophilia counseling for, 247
Subplate zone neurons, functional role of, 277
Substance abuse, maternal, fetal growth restriction and, 128
Systemic lupus erythematosus (SLE), 223-225

Tacrolimus, 366
TA-GVHD (transfusion-associated graft *versus* host disease), 265
Tetracaine, 324-325
α-Thalassemia syndromes, 255
Thrombocytopenia, heparin-induced, 252
Thromboembolism
  in pregnancy, 227-230
    anticoagulation therapy for, 170-172
    deaths from, 167
    delivery considerations, 229-230
    evaluation for, 169
    fetal surveillance, 172
    future research directions, 173
    implications for family members, 173
    management at time of delivery, 172
    postpartum management, 172
    prophylactic anticoagulation, 170, 227-228
    recurrence
      epidemiology of, 167-168
      risk factors for, 168-169
    therapeutic anticoagulation during pregnancy, 228-229
  venous neonatal, 250-253
    future research issues, 253
    therapy for, 251-252
Thrombolytic therapy, 252
Thrombophilias
  maternal
    fetal growth restriction and, 128, 131-132
    inherited, adverse pregnancy outcome risk and, 209-210
    parental counseling for, 247
    recurrent thromboembolism in pregnancy and, 168
    SGA infants and, 214
    testing for, 170
  perinatal, arterial ischemic stroke and, 244
Thrombosis
  associated with central catheters, 251
  history of
    evaluation, 169
    pregnant women with, anticoagulation protocols for, 171
Topical anesthetics, 323-328
  for circumcision, 326-327
  for heel lance, 327-328
  during intravenous cannulation, 325
  for lumbar puncture, 326

Topical anesthetics, 323-328 (*Continued*)
for peripherally inserted central catheters, 325-326
for venipuncture or arterial puncture, 324-325
Total blood volume, of preterm infants, 102
Total parenteral nutrition (TPN)
for short bowel syndrome, 105-107
usage guidelines, 69
Trace minerals, for parental nutrition, 106-107
Tracheal intubation
adverse physiological effects, 312, 315
premedication, 309-316
regimens, comparison of, 313-315
use in clinical practice, 312
vs. awake intubation, 310-311
Transdermal contraceptive patch (Ortho Evra®), for transplant recipients, 375
Transfusion-associated graft *versus* host disease (TA-GVHD), 265
Transfusions, perinatal. *See* Blood product replacement, in perinatal period
Transfusion-transmitted diseases, risk reduction, 265
Transplant recipients
contraception for, 372-376
female, prevalence of, 372
immunosuppressive therapy for (*See* Immunosuppressive drugs)
Triazoles, for neonatal *Candida* infections, 41
Triploidy, fetal growth restriction and, 126
Trophic feedings, *vs.* enteral feedings, 63-64
Trophoblast, differentiation/invasion, 205-206
Tumor necrosis factor-α, 4, 205
Twin gestation, recurrent spontaneous preterm birth and, 145-146

Ultrasound assessment, of uteroplacental circulation, 232-238
qualitative and quantitative, 237-238
qualitative and semi-quantitative, 236-237
quantitative, 232-236
Uniparental disomy (UPD), fetal growth restriction and, 127
United Kingdom Transplant Registry, 350
United States
diabetes prevalence in, 178-179
prevalence of pre-diabetic risk factors in, 178
UPD (uniparental disomy), fetal growth restriction and, 127
Ureaplasma infections
BPD development and, 4-5
chorioamnionitis and, 3
congenital neonatal pneumonia, 3-4
and future BPD research, 7
as human disease agent, 2-3
in inflammation and lung injury, 4
premature birth and, 3
treatment, impact on BPD in preterm neonates, 6-7
vertical transmission, 3
Ureaplasma parvum, 2, 5
Ureaplasma urealyticum, 2, 5
Uterine artery Doppler studies
in adverse pregnancy outcome prediction, 209-210
effect of gestational age on, 233-235
in evaluating FGR risk, 131
in first trimester, 235
in prediction of preeclampsia, 235-236
Uterine artery embolization, recurrent postpartum hemorrhage and, 161
Uterine invasion, recurrent postpartum hemorrhage and, 162
Uteroplacental circulation
multigate spectral Doppler analysis of, 237-238
qualitative and semi-quantitative assessment of, 237-238
quantitative assessment of, 232-236
Uteroplacental interface, adverse pregnancy outcomes and, 208-209

Vaginal ring (NuvaRing®), for transplant recipients, 375
Vancomycin-resistant enterococci (VRE), 27-28
Vascular disease, maternal, fetal growth restriction and, 128
Venipuncture, topical anesthesia for, 324-325
Venous thromboembolism, neonatal, 250-253
Ventilated neonates, routine sedation for, 289-290
Very low birth weight infants (VLBW). *See also* Enteral feedings, for high-risk infants
anthropometric assessment of, 96-100
enteral feeding regimens, 77-79
laboratory assessment of, 100-102
macronutritent requirements for, 74-77
nutritional management of (*See* Nutritional management, of VLBW infants)
postnatal growth studies, 48-50
Viral culture, HSV infection, 21
Vitamin A, 90-91
Vitamin K agonist therapy, 252
VLDL *vs.* toxicity-preventing activity hypothesis, 138
Volume reduction, after RBC and platelet transfusions, 265
Von Willebrand disease, recurrent postpartum hemorrhage and, 162-163
Voriconazole, for neonatal *Candida* infections, 41
VRE (vancomycin-resistant enterococci), 27-28

Warfarin, 252
Weight-for-length, of VLBW infant, 97
Weight gain
assessment, in VLBW infants, 100
as pre-diabetic risk factor, 178
during pregnancy, FGR prevention and, 129-130

Xenobiotic-metabolizing genes, SGA infants and, 214-215

Zinc, 106
Zygote, 204, 205